CJC-1295 (no DAC)
Also known as Mod GRF 1-29, Modified GRF (1-29), CJC-1295 without DAC
CJC-1295 without DAC is a modified GRF(1-29) peptide studied as a short-acting GHRH-receptor analog. A research profile: what the four substitutions do, why 'no DAC' matters, and its research contexts.
The single most confusing thing about CJC-1295 is that the name is sold as two very different molecules. This page is the one without the Drug Affinity Complex — often labelled 'Mod GRF 1-29' — and the whole reason it exists as its own SKU is that removing the DAC removes the long half-life. What is left is a short-acting analog of growth-hormone-releasing hormone.
Everything here is descriptive: its relationship to native GHRH, the four substitutions in its sequence, and the research contexts it appears in. No outcomes, no dosing — those are neither settled nor appropriate to claim for a research compound.
A tetra-substituted analog of GRF(1-29) — the first 29 residues of growth-hormone-releasing hormone. Four amino-acid substitutions (a D-alanine at position 2, plus changes at positions 8, 15 and 27) are introduced to slow enzymatic breakdown relative to native GHRH. Critically, this version carries no Drug Affinity Complex, so it is the 'short' form of the molecule.
What 'GHRH analog' actually means here
Growth-hormone-releasing hormone is the body's own signal, released from the hypothalamus, that tells the pituitary to secrete growth hormone. Its active core sits in the first 29 amino acids, a fragment researchers call GRF(1-29). CJC-1295 (no DAC) is a chemically tweaked version of exactly that fragment — it engages the same GHRH receptor rather than the separate ghrelin receptor used by secretagogues like ipamorelin or the GHRPs.
That receptor distinction is the axis this whole product cluster turns on. GHRH analogs and ghrelin mimetics are studied side by side precisely because they are two different doors into the same room.
The four substitutions, and why 'no DAC' is the point
Native GRF(1-29) is degraded quickly by the enzyme DPP-IV and by other proteases. The four substitutions in this analog — including a D-alanine swap at position two — are there to blunt that degradation, giving the peptide more stability than the unmodified fragment.
What this version does not have is the Drug Affinity Complex: the maleimide linker that, in the DAC variant, binds to circulating albumin and stretches the half-life out to days. Without it, the modified GRF(1-29) is comparatively short-lived in solution. That is not a defect — it is the defining feature that separates this SKU from CJC-1295 with DAC, and the reason the two are studied under different pulsatility profiles.
How it shows up in research alongside secretagogues
In the literature, a GHRH analog like this is frequently paired with a ghrelin-receptor agonist — the combination of the two mechanisms is the basis for the popular CJC-1295 / ipamorelin research stack. The GHRH-analog side and the secretagogue side are studied together because they act on distinct receptors.
When comparing certificates of analysis, note that a 'no DAC' lot should mass-match a 29-residue peptide without the added linker mass. If a certificate reports the DAC-conjugate mass under a 'no DAC' label, the two products have been confused.
These are research areas the compound is associated with in the literature — not medical claims or intended uses.
Handling & storage
Supplied lyophilized. Kept sealed and cold; in research settings reconstituted with bacteriostatic water only as a protocol requires, then refrigerated. Its shorter working stability is a reason handling notes matter for this variant specifically.
Verify a certificate by lot →Common questions
The DAC (Drug Affinity Complex) is an added linker that binds serum albumin and greatly extends half-life. This 'no DAC' version omits it, so it is short-acting. They are studied as two distinct molecules for that reason.
Yes — 'Modified GRF 1-29' is the common alternate name for the no-DAC form: a tetra-substituted analog of the GRF(1-29) core of GHRH.
No. This is a GHRH-receptor analog, while ipamorelin and the GHRPs act on the ghrelin (GHS) receptor. That is why the two classes are often studied together.
This monograph is a research-use reference. It describes composition and the contexts in which the compound has been studied — it is not medical advice, a description of effects, or a recommendation for use. Sold strictly for laboratory and research use; not for human or animal consumption.